Alaunos Therapeutics
TCRT
122 hedge funds and large institutions have $52.9M invested in Alaunos Therapeutics in 2022 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 22 increasing their positions, 31 reducing their positions, and 25 closing their positions.
2,010% more call options, than puts
Call options by funds: $5.61M | Put options by funds: $266K
0.01% less ownership
Funds ownership: 0.23% → 0.22% (-0.01%)
8% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 25
2% less funds holding
Funds holding: 125 → 122 (-3)
29% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 31
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
59% less capital invested
Capital invested by funds: $128M → $52.9M (-$75.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SGCA
Steel Grove Capital Advisors
Memphis,
Tennessee
|
+$1.59M |
| 2 |
Renaissance Technologies
New York
|
+$1.53M |
| 3 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$1.49M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$1.45M |
| 5 |
Two Sigma Investments
New York
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$2.32M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.46M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$782K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$765K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$602K |
TCRT Hedge Fund Activity: Q4 2022 in Review
122 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q4 2022, worth a combined $52.9M — down 59% from $128M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of TCRT and 23 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 22 added.
The largest buyer was Steel Grove Capital Advisors, adding an estimated $1.59M. The largest seller was State Street, cutting an estimated $2.32M.
- 122 institutional investors held Alaunos Therapeutics (TCRT) as of Q4 2022, down from 125 in Q3 2022.
- Funds reported $52.9M of Alaunos Therapeutics stock for Q4 2022, down 59% quarter-over-quarter.
- 23 funds opened new Alaunos Therapeutics positions in Q4 2022 and 25 closed out, a net change of -2 holders.
- The largest Alaunos Therapeutics buyer in Q4 2022 was Steel Grove Capital Advisors, an estimated $1.59M added.
- The largest Alaunos Therapeutics seller in Q4 2022 was State Street, an estimated $2.32M sold.
Based on aggregated 13F filings for Q4 2022.